London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Highlights · Statutory profit of RMB14.7m due to new fair valuation of Company's plantation · Underlying profit of RMB1.7m Statement I am pleased to be able to report that the recovery in Taihua plc ("Taihua") continued in 2010 H1. The results were significantly affected by implementation of accounting standards relating to our Chinese Yew plantation. We reported profit of RMB14.7m. RMB13.0m of which was in respect of a change in the basis of measurement of our plantation from cost to fair value based on its future cashflows. This change was required under IAS41 once its fair value could be reliably measured as its trees approached maturity. The remaining RMB1.7m was in respect of the trading in the period.
I bought into these a few months back as their p/e ratio looked promising and they seem to produce a drug which is effective against breast cancer. I think they had some production problems last year and this tie up deal with a European distributor is never ending. Cannot find out too much about them neither. Any information or prediction would be we welcome. I like the share but but I am in the dark about it a bit.
Price of this should soar on announcement of the new European distributors. DYOR
Why sell shares in a company that has a patent approved for a cancer drug? Worst case scenario for this in my opinion would be taken over by a bigger player. I'm definetly not saying that is imminnet but talking years down the line. When the Paclitaxel patent was approved within a day or so this company then issued a profits warning.. great news followed by now so good news. This time i believe it will be the reverse i believe it will be the profit warning now followed by news in March about who is the distributor.
Totally expected (if you are sensible and not a ramper) Anyone thinking different was living on the moon. Remains a large avoid IMO. RNS Number : 8919G Taihua Plc 09 February 2010 TAIHUA PLC ("Taihua" or "the Company") TRADING UPDATE Taihua plc a China-based pharmaceutical company which manufactures Paclitaxel, Homoharringtonine and Traditional Chinese Medicines ("TCM") would like to update its shareholders on its progress in 2009 before the release of its financial results for the 12 months ended 31 December 2009. Overview As disclosed in the AGM Statement of 24 July 2009 and the 2009 interim results of the Company, the first half of 2009 was very difficult for the business of Taihua. Impacted by the global financial crisis and foreign exchange rate fluctuations, the sales volume of Paclitaxel and Homoharringtonine, the Company's principal products, had decreased when compared to the same period in 2008. The Company's customers' demands increased in the second half of 2009 compared to the first half of 2009 (Paclitaxel sales in H1: 4750 grams; Pacliataxel sales in H2: 6805 grams (an increase of 43.26%) and homoharringtonine sales in H1: 1620 grams and homoharringtonine sales in H2: 3570 grams (an increase of 120%)). However, the increase was not sufficient to arrest the decline in year end profits compared with the previous year. Therefore, although the trading performance of the Company has improved in the second half of 2009, the sales volume of Paclitaxel and homoharringtonine in 2009, as affected by the poor performance in the first half of 2009, was still lower than that in 2008. Paclitaxel and Homoharringtonine The prices of Paclitaxel and Homoharringtonine remained unchanged in the second half of 2009. During 2009, the Company sold 11,555 grams of Paclitaxel, a decrease of 31% compared to 2008, and 5,190 grams of Homoharringtonine, a decrease of 43% compared to 2008. TCM products The Company has not fully recovered from the adverse influence of the suspension of TCM production in 2008. As a result, the sales revenue of TCM products in 2009 decreased by 9% compared to 2008. Outlook The Company is now concentrating on further discussions with potential European distributors and expects to conclude the negotiations with potential European distributors in March 2010.
I know this may sound like a silly question but when are this companies reports due out again?
I know this may sound like a silly question but when are this companies reports due out again?
Its probably being dragged down by Lloyds due to the RI, plus the masses selling out in fear of a big retrace in the FTSE.
Hi guys whats happening with rbs thier falling like a stone lately i thought thier were climbimbing well last month?
big rise on no news - does anyone know if we are waiting on something in near future
Where is this profits warning ? looking for it but cant find it ??
Theres been a profits warning chaps. Time to move on and out in my opinion
Whats happening here, went up to 18p after news of acceptance into Europe then drops ????
From the Guardian Finally Chinese pharmaceutical manufacturer Taihua added 6.625p to 15.5p as the company was granted a certificate of suitability to sell its ingredients for the anti-cancer drug Paclitaxel in Europe. The drug is widely used in the treatment of lung, breast and ovarian cancers. Taihua already sells Paclitaxel ingredients to drug manufacturers in Russia and South America, and the certificate clears the way for sales into Europe.
On this Company 2007: http://www.growthcompany.co.uk/recommendations/257689/taihua.thtml Paclitaxel has passed all necessary regulatory hurdles around the world, but for Taihua to supply to pharma companies in the £1.25bn European market it will need to garner its own EU approval. Further on, it will go through the same process for homoharringtonine, which has anti-leukaemia properties, and even further on an own-brand injection is planned. Barchart has upgrade tonight from a 72% buy to 100% http://quote.barchart.com/texpert.asp?sym=TAIH.LS&code=BSTK THey can now supply this cancer drug paclitaxel in Europe to a £1.26bn market. What paclitaxel is Paclitaxel is a chemotherapy drug. It is also known by its brand names, Taxol and Abraxane. The drug comes from the bark of one particular type of yew tree. It works by stopping cancer cells separating into two new cells, so it blocks the growth of the cancer. It is a treatment for ovarian cancer breast cancer non small cell lung cancer. So a large market. Good luck all, some surprise news.
Think this will just rise in 5-10 % over next few weeks unless contracts come in then we are away
Looking at yahoo finance and it is showing this share price at 10p yet on LSe it is at 15.50 what is the correct share price for this share?
Very new to share dealing. I bought this share at 8p and now it's at 15p a share. Does anyone think this share will rise even further short te/rm or long term? Will this company be loking to expand or grow or is it ripe for takeover etc ay advice greatly appreciated
well done to all long term holders> much more to come